TCRLAS v2.0 · WORKING DRAFT

Commercial viability. Evidence before decisions.

Record a five-dimension CVA profile with evidence. Explore and verify maturity in the separate milestone assessment. Scores never approve an investment or launch.

Private by design: this browser-only draft is held in memory. Refreshing, leaving this page or closing it loses unsaved work. Export your JSON for safekeeping and import it to continue. No automatic storage, accounts, database or submission. Do not enter patient-identifiable information or confidential business details. JSON exports are unencrypted.

Assessment scope

Independent maturity record

Milestone: NE — not assessed.

CVA and HSE never assign maturity. Export this record, open the milestone tool, and import it there to review maturity. Import its exported record here to continue. All profiles and evidence remain in the complete JSON.

Open independent milestone assessment →

Commercial Viability Assessment (CVA)

Scores are ordinal evidence anchors, not probabilities. NE is unassessed. A zero needs an adverse evidence rationale. HSE N/A requires a documented applicability reason, reviewer and date; it is never converted into a score.

M — Market Opportunity

Is an economically meaningful and accessible customer market worth pursuing?

Inspect all M evidence anchors (0–6)
  1. 0: No credible customer, need or viable accessible market identified; or fundamental demand proposition disproven.
  2. 1: Plausible need and potential users/buyers hypothesized, without meaningful independent evidence.
  3. 2: Customer types, alternatives and approximate addressable market investigated with preliminary external information.
  4. 3: Specific reachable segment, purchasing pathway, demand and willingness-to-pay assumptions credibly documented.
  5. 4: Independent customers or purchasing authorities substantiate demand and feasible access to initial market.
  6. 5: Representative external demand and concrete procurement or commercial signals support market depth and acquisition assumptions.
  7. 6: Repeatable demand in a representative segment with credible continuing access and growth potential demonstrated.
M evidence, confidence and rationale
C — Competitive Advantage

Why would the buyer prefer the offering, and can the advantage persist?

Inspect all C evidence anchors (0–6)
  1. 0: No credible customer-relevant difference or insurmountable known use-rights issue.
  2. 1: Advantage asserted without meaningful comparison.
  3. 2: Preliminary comparisons of performance, cost, usability, rights or access identify plausible advantage.
  4. 3: Documented material advantage, alternatives and key imitation/rights risks with credible competitive strategy.
  5. 4: Independent testing, buyers or market evidence supports advantage, and protection path is credible.
  6. 5: Advantage externally supported under realistic competitive comparison; important imitation/rights issues managed.
  7. 6: Durable advantage demonstrated through continued customer preference, economics, know-how, rights or switching barriers.
C evidence, confidence and rationale
E — Commercial Economics

Does further investment have a credible path to sufficient economic value?

Inspect all E evidence anchors (0–6)
  1. 0: No viable economics or demonstrably untenable costs with no plausible remedy.
  2. 1: Revenue and cost hypotheses only.
  3. 2: Preliminary prices, product/service delivery costs, capital needs and sources estimated.
  4. 3: Documented margin, cash requirement and break-even model with credible assumptions and sensitivities.
  5. 4: Important pricing and costs externally substantiated; plausible economics demonstrated for proposed route.
  6. 5: Strong evidence of attractive unit economics and realistic capital needs resilient to material scenarios.
  7. 6: Sustained or repeatably validated economics under relevant conditions with credible financing and growth path.
E evidence, confidence and rationale
X — Execution Capability

Can accountable parties deliver the specified next milestone?

Inspect all X evidence anchors (0–6)
  1. 0: No feasible execution route; indispensable capabilities/resources inaccessible.
  2. 1: Possible team, partners, licensing path or resources merely identified.
  3. 2: Initial roles, budgets, dependencies and delivery partners identified.
  4. 3: Milestone-specific owners, budget, schedule, dependencies and potential partners credibly documented.
  5. 4: Key owners, partners and resources supported by verifiable commitments for next milestone.
  6. 5: Proven delivery capability and adequate available/accessible resources with contingency for major milestone.
  7. 6: Repeatable resilient execution through capable organization/contracted partners without single-point dependence.
X evidence, confidence and rationale
R — Risk Manageability

Are risks identified and controlled sufficiently for the proposed action?

Inspect all R evidence anchors (0–6)
  1. 0: Established fatal unmanageable risk for proposed action.
  2. 1: Material uncertainty largely unexamined; no credible controls.
  3. 2: Key legal, safety, technical, financial, operational and commercial uncertainties preliminarily registered.
  4. 3: Dated risk register with consequence, uncertainty, owner, mitigation and resolution evidence milestones.
  5. 4: Major risks have supported mitigations, contingencies and clear validation milestones.
  6. 5: Major exposures controlled or reduced; residual risk acceptable for defined next activity and triggers documented.
  7. 6: Controls demonstrably effective under relevant adverse scenarios and sustained monitoring.
R evidence, confidence and rationale

Critical blocker register

Record which activity a blocker affects. A restriction on launch does not by itself prohibit lawful preparatory research.

Commercialization Decision (CDA)

A named human reviewer records a bounded next-action decision. ADVANCE does not authorize launch.

Read the decision guide →

Unassessed decision: no authorization recorded.

Commercial Launch Decision

Separate named human review for a defined offering, scope and jurisdiction. GO is never produced by scores or checklist completion. CONDITIONAL refers only to activities already permitted.

Read the decision guide →

Applicable launch requirements

Scope being reviewed

Jurisdiction: not specified
Intended use: not specified
Claims: not specified

Qualified reviewers determine each requirement’s applicability for this exact scope. Changing scope clears previous requirement reviews.

These prompts are a working framework, not an exhaustive legal checklist. Review each against intended use, claims and jurisdiction with qualified people. Unreviewed or unresolved mandatory requirements prevent recording GO/CONDITIONAL.

Offering, intended use, claims, users, jurisdiction and launch scope — unreviewed
Offering, intended use, claims, users, jurisdiction and launch scope evidence
Applicable legal permissions and qualified review — unreviewed
Applicable legal permissions and qualified review evidence
Evidence supports claims and intended benefits — unreviewed
Evidence supports claims and intended benefits evidence
Delivery, accountable owners, continuity, support and incident controls — unreviewed
Delivery, accountable owners, continuity, support and incident controls evidence
Buyer/payment route, pricing, costs and available capital — unreviewed
Buyer/payment route, pricing, costs and available capital evidence
Named decision authority and documented review — unreviewed
Named decision authority and documented review evidence

Unassessed decision: no authorization recorded.